Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease

다국어 초록 (Multilingual Abstract)

Background: Randomized controlled trials demonstrated lowering risks of cardiovascular events with sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk. We analyzed the effects of cardiovascular function on SGLT2 inhibitors compared with dipeptidyl peptidase-4 (DPP4) inhibitors in T2DM with atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF).
Methods: This is a retrospective, observational, single center study. Data from 89 patients with ASCVD or HF from January 2015 to February 2018 were analyzed regarding the effect of SGLT2 inhibitors and DPP4 inhibitors. Cardiovascular function was assessed by 2-D echocardiography and N-terminal prohormone of brain natriuretic peptide (NT-pro BNP).
Results: A total of 89 patients with T2DM were considered in two groups of SGLT2 inhibitors (n=41) and DPP4 inhibitors (n=48). The mean follow-up period was 2 years, with a total of 89 patient-years. Despite no significant change in systolic function, SGLT2 inhibitors improved cardiovascular function, as demonstrated by a reduced left ventricular ejection fraction less than 40%, ratio of mitral peak velocity of early filling velocity to early diastolic mitral annular velocity, ratio of early to late ventricular filling velocities, and NT-pro BNP compared with the DPP4 inhibitor group.
Conclusion: SGLT2 inhibitors improve cardiovascular function in T2DM with coronary artery disease compared to DPP4 inhibitors.

참고문헌 (Reference)

1 Secrest MH, "The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors" 27 : 194-202, 2017

2 Scirica BM, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus" 369 : 1317-1326, 2013

3 Verma S, "SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review" 61 : 2108-2117, 2018

4 Abdelgadir E, "SGLT-2 inhibitors and cardiovascular protection: lessons and gaps in understand ing the current outcome trials and possible benefits of combining SGLT-2 inhibitors with GLP-1 agonists" 10 : 615-625, 2018

5 Kosiborod M, "Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice:results from the CVD-REAL study" 20 : 1983-1987, 2018

6 Natali A, "Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial" 16 : 130-, 2017

7 Scirica BM, "Heart failure, saxagliptin, and diabetes mellitus:observations from the SAVOR-TIMI 53 randomized trial" 130 : 2014

8 Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes" 373 : 2117-2128, 2015

9 조현아, "Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus" 대한비만학회 26 (26): 107-113, 2017

10 Verma S, "Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG outcome trial?" 39 : e212-e213, 2016

11 Korean Diabetes Association, "Diabetes fact sheet in Korea 2013" Korean Diabetes Association 2013

12 Wiviott SD, "Dapagliflozin and cardiovascular outcomes in type 2 diabetes" 380 : 347-357, 2019

13 Lambers Heerspink HJ, "Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes" 15 : 853-862, 2013

14 Cefalu WT, "Cardiovascular outcomes trials in type 2 diabetes:where do we go from here? Reflections from a diabetes care editors’ expert forum" 41 : 14-31, 2018

15 Kosiborod M, "Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study" 71 : 2628-2639, 2018

16 Scheen AJ, "Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors" 122 : 1439-1459, 2018

17 Thompson PL, "Cardiovascular effects of glucoselowering therapies for type 2 diabetes: new drugs in perspective" 39 : 1012-1025, 2017

18 Neal B, "Canagliflozin and cardiovascular and renal events in type 2 diabetes" 377 : 644-657, 2017

19 Mudaliar S, "Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis" 39 : 1115-1122, 2016

20 Ferrannini E, "CV protection in the EMPAREG OUTCOME trial: a “thrifty substrate” hypothesis" 39 : 1108-1114, 2016

21 Kim YG, "Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study" 17 : 91-, 2018